Literature DB >> 8851652

Venlafaxine in the treatment of borderline personality disorder.

P J Markovitz, S C Wagner.   

Abstract

A number of studies have indicated that selective serotonin reuptake inhibitors (SSRIs) are effective in reducing the symptomatology accompanying borderline personality disorder (BPD). The SSRIs have proven efficacious in reducing self-injury, suicidality, affective instability, rage, impulsivity, psychosis, and obsessionality. Fluoxetine and sertraline have been shown to be effective in clinical trials, although no single SSRI has emerged as the treatment of choice. Individuals failing one SSRI often respond to another. The data presented in this article indicate that venlafaxine is effective in treating borderline personality disorder (BPD) as an initial intervention and may benefit many individuals for whom fluoxetine or sertraline treatment has failed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8851652

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  8 in total

Review 1.  Update on pharmacotherapy of borderline personality disorder.

Authors:  Mary C Zanarini
Journal:  Curr Psychiatry Rep       Date:  2004-02       Impact factor: 5.285

2.  Self-mutilation and pharmacotherapy.

Authors:  Brian Daniel Smith
Journal:  Psychiatry (Edgmont)       Date:  2005-10

Review 3.  Pharmacotherapy for borderline personality disorder--current evidence and recent trends.

Authors:  Jutta M Stoffers; Klaus Lieb
Journal:  Curr Psychiatry Rep       Date:  2015-01       Impact factor: 5.285

Review 4.  Treating nonsuicidal self-injury: a systematic review of psychological and pharmacological interventions.

Authors:  Brianna J Turner; Sara B Austin; Alexander L Chapman
Journal:  Can J Psychiatry       Date:  2014-11       Impact factor: 4.356

Review 5.  Suicidal and self-injurious behavior in personality disorder: controversies and treatment directions.

Authors:  Jessica Gerson; Barbara Stanley
Journal:  Curr Psychiatry Rep       Date:  2002-02       Impact factor: 5.285

Review 6.  Pharmacological interventions for borderline personality disorder.

Authors:  Jutta Stoffers; Birgit A Völlm; Gerta Rücker; Antje Timmer; Nick Huband; Klaus Lieb
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16

Review 7.  Medications in the treatment of borderline personality disorder 2006.

Authors:  Deanna Mercer
Journal:  Curr Psychiatry Rep       Date:  2007-02       Impact factor: 8.081

Review 8.  Current Clinical Psychopharmacology in Borderline Personality Disorder.

Authors:  Antonio Del Casale; Luca Bonanni; Paride Bargagna; Francesco Novelli; Federica Fiaschè; Marco Paolini; Francesca Forcina; Gaia Anibaldi; Francesca Natalia Cortese; Alessia Iannuccelli; Barbara Adriani; Roberto Brugnoli; Paolo Girardi; Joel Paris; Maurizio Pompili
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.